| 11.07 Data as of May 23 |  +0.09 / +0.82%Today’s Change | 5.72 Today|||52-Week Range 14.46 | +23.27% Year-to-Date |
| Pipeline Progress at Gilead - Analyst Blog May 16 / Zacks.com |
| Previous close | 10.98 |
| Today’s open | 10.84 |
| Day’s range | -- - -- |
| Volume | 78,794 |
| Average volume (3 months) | 141,015 |
| Market cap | $361.6M |
| Dividend yield | -- |
| Earnings growth (last year) | -175.56% |
| Earnings growth (this year) | +10.29% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -72.16% |
| P/E ratio | NM |
| Price/Sales | 25.00 |
| Price/Book | 10.06 |
| Today’s change | Today’s % change | |
|---|---|---|
| HPTXHyperion Therapeutic... | +0.16 | +0.79% |
| NVAXNovavax Inc | -0.01 | -0.49% |
| CRISCuris Inc | +0.08 | +2.16% |
| PLXProtalix Biotherapeu... | -0.01 | -0.19% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.09 |
| Annual revenue (last year) | $11.8M |
| Annual profit (last year) | -$11.1M |
| Net profit margin | -93.74% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman Peter A. Friedli |
President, Chief Executive Officer & Director Charles Randal Mills, PhD |
Corporate headquarters Columbia, Maryland |
.
